N/o-linked degrons and degronimers for protein degradation

A compound of Formula:

• or a pharmaceutically acceptable salt thereof;
• wherein:
• n is 0 or 1;
• R5 is hydrogen, C1-C3alkyl, F, Cl, Br, hydroxyl, C1-C3alkoxy, amino, cyano, —NH(C1-C3alkyl), —N(C1-C3alkyl)2, C(O)R4, or C1-C3haloalkyl;
• R4 is hydrogen, C1-C3alkyl, hydroxyl, C1-C3alkoxy, amino, —NH(C1-C3alkyl), —N(C1-C3alkyl)2, or C1-C3haloalkyl;
• R12 is Linker-Targeting Ligand;
• Linker is a chemical group of formula:
• wherein:
• X1 and X2 are independently selected from the group consisting of bond, NH, and NC1-C3alkyl;
• R20, R21, R22, R23, and R24 are independently selected from the group consisting of bond, C1-C3alkyl, —C(O)—, —C(O)O—, —OC(O)—, —C(O)C1-C3alkyl, —C(O)OC1-C3alkyl, —C(O)NH—, —NHC(O)—, —N(C1-C3alkyl)C(O)—, —C(O)N(C1-C3alkyl)-, —O—, —NH—, —N(C1-C3alkyl)-, C1-C3alkoxy, phenyl, and 6-membered heterocycle with one or two nitrogen atoms;
• each of which R20, R21, R22, R23, and R24 is optionally substituted with one substituent selected from R101;
• R101 is independently selected at each occurrence from the group consisting of C1-C3alkyl, C1-C3haloalkyl, and F;
• and
• Targeting Ligand is a ligand that binds to an androgen receptor, wherein the Targeting Ligand is of formula:
• wherein:
• R is the point at which the Linker is attached.